New pill targets leukemia's genetic weak spot in landmark trial
NCT ID NCT07223814
First seen Nov 03, 2025 · Last updated May 01, 2026 · Updated 22 times
Summary
This phase 3 trial tests whether adding the experimental drug bleximenib to standard chemotherapy improves outcomes for adults with newly diagnosed acute myeloid leukemia (AML) that has a KMT2A rearrangement or NPM1 mutation. Bleximenib blocks a protein interaction that helps leukemia cells survive. About 875 participants will receive either bleximenib or a placebo alongside chemo, followed by maintenance therapy. The study is double-blind, so neither patients nor doctors know who gets the active drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
DE-Ulm-UNIKLINKULM
RECRUITINGUlm, Germany
Contact
-
NL-Breda-AMPHIA
RECRUITINGBreda, Netherlands
Contact
-
NL-Den Haag-HAGA
RECRUITINGThe Hague, Netherlands
Contact
-
NL-Eindhoven-MAXIMAMC
RECRUITINGEindhoven, Netherlands
Contact
-
NL-Leeuwarden-FRISIUSMC
RECRUITINGLeeuwarden, Netherlands
Contact
-
NL-Nieuwegein-ANTONIUS
RECRUITINGNieuwegein, Netherlands
Contact
-
NL-Rotterdam-ERASMUCMC
RECRUITINGRotterdam, Netherlands
Contact
-
US-Cincinnati OH-CINCY
RECRUITINGCincinnati, Ohio, 45219, United States
Contact
Conditions
Explore the condition pages connected to this study.